eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Novartis Pharmaceuticals UK Ltd
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 12/12/2011
PIL Rasilez 300 mg film-coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 12/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change of contra-indications
  • Change to side-effects
Updated on 13/06/2011 and displayed until 12/12/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
Updated on 14/03/2011 and displayed until 13/06/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 09/12/2010 and displayed until 14/03/2011
Reasons for adding or updating:
  • Change to drug interactions
Updated on 01/07/2010 and displayed until 09/12/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 27/04/2009 and displayed until 01/07/2010
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to drug interactions
Updated on 15/09/2008 and displayed until 27/04/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to drug interactions
Updated on 23/04/2008 and displayed until 15/09/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 06/09/2007 and displayed until 23/04/2008
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  aliskiren hemifumarate